Advertisement

Topics

Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

07:42 EDT 3 Nov 2017 | BioPortfolio Reports

Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 Pipeline Review, H2 2017


Summary


Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies. The latest report Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 Pipeline Review, H2 2017, outlays comprehensive information on the Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 Protein kinase C PKC is an enzyme belonging to a family of serine and threoninespecific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders and Oncology which include indications Alzheimer's Disease, Acid Sphingomyelinase Deficiency NiemannPick Disease Type C, Alcohol Addiction, Fragile X Syndrome, Head And Neck Cancer, Ischemic Stroke, Neurology, Rett Syndrome and Traumatic Brain Injury.


Furthermore, this report also reviews key players involved in Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13

The report reviews Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Protein Kinase C Epsilon Type nPKC Epsilon or PRKCE or EC 2.7.11.13 Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500"

Quick Search
Advertisement
 

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...